Abstract
There is growing evidence that inflammatory bowel disease has a preclinical phase that precedes disease symptoms, during which immune system activation has already occurred and inflammatory pathways have been primed, setting the stage for disease to expand and leading up to clinical diagnosis. Gaining insight to this pre-diagnosis period could improve our knowledge about disease pathogenesis and potentially result in the detection of biomarkers that could predict disease development. The ultimate goal of such research is to identify a population at risk for developing IBD, so preventive strategies could be implemented and disease prevention be achieved.
Original language | English |
---|---|
Pages (from-to) | 110-115 |
Number of pages | 6 |
Journal | Current Opinion in Pharmacology |
Volume | 55 |
DOIs | |
Publication status | Published - Dec 2020 |
Externally published | Yes |